Tuis500124 ā¢ BOM
add
Dr Reddy's Laboratories Ltd
Vorige sluiting
ā¹1Ā 132,80
Dagwisseling
ā¹1Ā 116,30 - ā¹1Ā 137,15
Jaarwisseling
ā¹1Ā 104,55 - ā¹1Ā 420,20
Markkapitalisasie
933,10Ā mjd INR
Gemiddelde volume
67,80Ā k
P/V-verhouding
17,39
Dividend-opbrengs
0,71%
PrimĆŖre beurs
NSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(INR) | Des. 2024info | J/J-verandering |
---|---|---|
Inkomste | 83,59Ā mjd | 15,85% |
Bedryfskoste | 30,34Ā mjd | 19,95% |
Netto inkomste | 14,13Ā mjd | 2,49% |
Netto winsgrens | 16,91 | -11,51% |
Wins per aandeel | 16,94 | 1,81% |
EBITDA | 23,43Ā mjd | 13,31% |
Effektiewe belastingkoers | 25,10% | ā |
Balansstaat
Totale bates
Totale aanspreeklikheid
(INR) | Des. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 59,92Ā mjd | -17,41% |
Totale bates | 481,06Ā mjd | 29,02% |
Totale aanspreeklikheid | 159,49Ā mjd | 51,91% |
Totale ekwiteit | 321,56Ā mjd | ā |
Uitstaande aandele | 833,12Ā m | ā |
Prys om te bespreek | 2,97 | ā |
Opbrengs op bates | 9,88% | ā |
Opbrengs op kapitaal | 12,81% | ā |
Kontantvloei
Netto kontantverandering
(INR) | Des. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 14,13Ā mjd | 2,49% |
Kontant van bedrywe | 6,62Ā mjd | 39,75% |
Kontant van beleggings | -5,46Ā mjd | 66,27% |
Kontant van finansiering | 590,00Ā m | -88,83% |
Netto kontantverandering | 1,75Ā mjd | 129,12% |
Beskikbare kontantvloei | -382,75Ā m | 90,46% |
Meer oor
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants ā in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
HUB
Gestig
1984
Hoofkwartier
Webwerf
Werknemers
27Ā 048